Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Short Interest Update

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) was the target of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 5,913 shares, an increase of 53.0% from the July 15th total of 3,865 shares. Currently, 4.5% of the shares of the stock are short sold. Based on an average trading volume of 3,042 shares, the days-to-cover ratio is presently 1.9 days.

Bitwise MARA Option Income Strategy ETF Price Performance

Bitwise MARA Option Income Strategy ETF stock opened at $14.59 on Tuesday. Bitwise MARA Option Income Strategy ETF has a 52-week low of $11.99 and a 52-week high of $42.32. The firm’s fifty day moving average is $15.72 and its 200 day moving average is $15.26. The company has a market cap of $1.90 million, a price-to-earnings ratio of 291.80 and a beta of 2.74.

Insider Buying and Selling at Bitwise MARA Option Income Strategy ETF

In related news, major shareholder Orbimed Advisors Llc sold 860,123 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $45.36, for a total value of $39,015,179.28. Following the completion of the transaction, the insider directly owned 219,405 shares of the company’s stock, valued at approximately $9,952,210.80. This trade represents a 79.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at $2,114,723.16. This represents a 19.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,342,362 shares of company stock worth $63,158,240. Company insiders own 37.30% of the company’s stock.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.